For a given cancer type, we estimated the ability of PD-L1 expression to stratify survival benefit for ICI versus standard-of-care based on the difference in reduced risk of death/progression between PD-L1+ and PD-L1- subgroups. This evidence concerns the gene CD274 and cancer.